CeriBell (NASDAQ:CBLL) Earns Buy Rating from Analysts at Bank of America

Bank of America began coverage on shares of CeriBell (NASDAQ:CBLL) in a research note released on Tuesday, Marketbeat.com reports. The brokerage issued a buy rating and a $32.00 price target on the stock.

Other analysts also recently issued research reports about the company. Canaccord Genuity Group started coverage on shares of CeriBell in a research note on Tuesday. They set a “buy” rating and a $30.00 price objective for the company. William Blair assumed coverage on shares of CeriBell in a research report on Tuesday. They issued an “outperform” rating for the company. JPMorgan Chase & Co. started coverage on shares of CeriBell in a research report on Tuesday. They set an “overweight” rating and a $32.00 price objective on the stock. Finally, TD Cowen started coverage on CeriBell in a report on Tuesday. They issued a “buy” rating and a $31.00 target price for the company. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $31.00.

CeriBell Stock Up 4.2 %

Shares of NASDAQ CBLL opened at $28.95 on Tuesday. CeriBell has a 52-week low of $23.00 and a 52-week high of $29.53.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.